Joule and Red Rock Biofuels Announce Intent to Merge, Creating an Industry-Leading Carbon-Neutral Fuel Production Platform

Joule and Red Rock Biofuels Announce Intent to Merge, Creating an Industry-Leading Carbon-Neutral Fuel Production Platform

November 12, 2015

Dr. Brian Baynes Named CEO Replacing Serge Tchuruk Who Will Continue in Board Role

BEDFORD, Mass. & FT. COLLINS, Colo.--(BUSINESS WIRE)--Joule, the pioneer of liquid fuels from recycled CO2, and Red Rock Biofuels, a leading developer of renewable jet and diesel fuel bio-refineries, today announced their intent to merge. Red Rock adds a proven technology pathway to Joule’s own Helioculture technology and strengthens Joule’s platform for global supply of carbon neutral fuels. The transaction is expected to close during the coming 30 days.

Syros Pharmaceuticals Announces Issuance of U.S. Patents Related to Its Gene Control Drug Discovery and Development Platform

Syros Pharmaceuticals Announces Issuance of U.S. Patents Related to Its Gene Control Drug Discovery and Development Platform

November 10, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals today announced that the U.S. Patent and Trademark Office issued two patents related to the Company’s proprietary gene control platform for mapping and drugging crucial genes that become dysregulated in disease. The covered inventions include methods for identifying specialized regions of DNA, known as super-enhancers, which are part of the foundation of the Company’s drug discovery and development platform.

Seres Therapeutics Appoints Kurt Graves to Board of Directors

Seres Therapeutics Appoints Kurt Graves to Board of Directors

November 10, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 10, 2015-- Seres Therapeutics Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today announced the appointment of Kurt Graves to the company’s board of directors. Mr. Graves, the Chairman, President and CEO of Intarcia Therapeutics, is an industry leader who brings to Seres extensive experience from his 25-year career at top-tier pharmaceutical and biotech companies.

Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

November 8, 2015

 - Safety Profile Confirmed; Signs of Clinical and Biological Activity Observed; Recommended Phase 2 Dose Selected -

- Phase 1 Expansion Cohorts for Patients with IDH1 Mutant Positive Glioma, Cholangiocarcinoma, Chondrosarcoma and Other Advanced Solid Tumors Are Open and Enrolling -

UChicago and Evelo Therapeutics Partner to Advance Microbiome-based Cancer Immunotherapy

UChicago and Evelo Therapeutics Partner to Advance Microbiome-based Cancer Immunotherapy

November 9, 2015

Agreement to collaborate on development of microbiome-based cancer therapies to boost patients’ immune systems

Cambridge, Mass., November 9, 2015/PRNewswire/ – A partnership between Evelo Therapeutics and the University of Chicago will advance an immunotherapy that employs certain gut microbes to boost the immune system’s attack on cancer cells and improve the effectiveness of anti-cancer drugs.

Agios Reports Third Quarter 2015 Financial Results

Agios Reports Third Quarter 2015 Financial Results

November 5, 2015

 – New AG-221 and AG-120 Data in Solid Tumors and Hematologic Malignancies to be Presented at AACR-NCI-EORTC and ASH Annual Meeting –

Pronutria Biosciences Announces Jennifer Che, J.D., as Vice President, Intellectual Property Counsel

Pronutria Biosciences Announces Jennifer Che, J.D., as Vice President, Intellectual Property Counsel

November 5, 2015

Cambridge, Mass., November 5th, 2015 / BUSINESS WIRE / -- Pronutria Biosciences™ Inc., a biotechnology company pioneering a new class of therapeutics to mediate amino acid biology, announced today the appointment of Jennifer Che, J.D., as Vice President, Intellectual Property Counsel. Ms. Che will oversee all intellectual property activities related to the protection of Pronutria’s technology and lead candidates.

Acceleron Pharma Reports Third Quarter 2015 Financial and Operational Results

Acceleron Pharma Reports Third Quarter 2015 Financial and Operational Results

November 4, 2015

- ACE-083 Phase 1 results demonstrate an unprecedented increase in muscle volume. Phase 2 clinical trials planned to start next year -

- ACE-2494 generates significant increases in muscle mass in preclinical studies. Phase 1 clinical trial of ACE-2494 planned to start next year -

- FDA granted Fast Track Designation for dalantercept in combination with axitinib for the treatment of patients with advanced renal cell carcinoma -

Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer

Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer

November 4, 2015

Breakthrough Innovations from Flagship VentureLabs Target the Cancer Microbiome

Industry Leader Simba Gill Ph.D. Appointed CEO

Cambridge, Mass., Nov. 4, 2015/PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability, announced it has launched Evelo Therapeutics, a new company focused on leveraging the power of the microbiome to develop novel therapies for cancer, with an initial capital commitment of $35 million.

China Food and Drug Administration (CFDA) Grants Approval for Avedro’s KXL® System

China Food and Drug Administration (CFDA) Grants Approval for Avedro’s KXL® System

November 3, 2015

Avedro is the first and only company to receive CFDA approval for corneal cross-linking